Stockscreener 앱 받기
7.05
5.75%
-0.43
시간 외 거래:
7.01
-0.04
-0.57%
전일 마감가:
$7.48
열려 있는:
$7.48
하루 거래량:
1.30M
Relative Volume:
4.05
시가총액:
$397.87M
수익:
-
순이익/손실:
$-72.89M
주가수익비율:
-2.9132
EPS:
-2.42
순현금흐름:
$-68.47M
1주 성능:
-5.11%
1개월 성능:
+11.90%
6개월 성능:
+11.73%
1년 성능:
-42.91%
1일 변동 폭
$6.86
$7.633
1주일 범위
$6.86
$7.83
52주 변동 폭
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
명칭
Astria Therapeutics Inc
전화
617-349-1971
주소
22 BOSTON WHARF ROAD, BOSTON
ATXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
7.05 | 422.13M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-29 | 개시 | TD Cowen | Buy |
| 2023-03-28 | 개시 | Evercore ISI | Outperform |
Astria Therapeutics Inc 주식(ATXS)의 최신 뉴스
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Market Moves: Can Astria Therapeutics Inc maintain its current growth rateTrade Entry Report & Daily Profit Focused Stock Screening - khodrobank.com
Published on: 2025-09-19 19:09:43 - newser.com
What’s the recovery path for long term holders of Astria Therapeutics Inc.Trade Volume Summary & Entry Point Confirmation Signals - newser.com
Aug Fed Impact: Is Astria Therapeutics Inc trading at a discountJuly 2025 Price Swings & Risk Controlled Daily Plans - khodrobank.com
Aug EndMonth: Can Astria Therapeutics Inc. maintain its current growth rateJuly 2025 PreEarnings & Real-Time Volume Analysis Alerts - khodrobank.com
Detecting price anomalies in Astria Therapeutics Inc. with AIJuly 2025 Breakouts & Free Community Consensus Stock Picks - newser.com
Chart based exit strategy for Astria Therapeutics Inc.Chart Signals & Momentum Based Trading Ideas - newser.com
Will Astria Therapeutics Inc. bounce back from current support2025 Price Targets & Smart Allocation Stock Reports - newser.com
Will breakout in Astria Therapeutics Inc. lead to full recoveryPortfolio Value Report & Low Drawdown Investment Strategies - newser.com
HC Wainwright Boosts Astria Therapeutics (NASDAQ:ATXS) Price Target to $20.00 - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology - Business Wire
Can Astria Therapeutics Inc. rally from current levelsDip Buying & Long-Term Safe Return Strategies - newser.com
Analysis Recap: Can Astria Therapeutics Inc scale operations efficiently2025 Pullback Review & Capital Efficiency Focused Ideas - khodrobank.com
Astria Therapeutics (ATXS) Target Price Raised by HC Wainwright & Co. | ATXS Stock News - GuruFocus
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of ST - PharmiWeb.com
Astria (ATXS) Successfully Completes STAR-0310 Phase 1 Trial - GuruFocus
ATXS: Cantor Fitzgerald Reiterates Overweight Rating with $49 Pr - GuruFocus
Astria Therapeutics Says STAR-0310 Showed Half-Life of 68 Days in Phase 1a Trial; Shares Up Pre-Bell - MarketScreener
Astria Therapeutics (ATXS) Reports Promising Phase 1a Trial Resu - GuruFocus
Astria Therapeutics : Corporate Presentation - MarketScreener
Astria reports positive phase 1a star-0310 trial results at European Dermatology & Venereology Congress - MarketScreener
$23.9M Q2 Revenue: Travelzoo's Club Membership Strategy Drives 13% Growth Despite EPS Impact - Stock Titan
Cubist Systematic Strategies LLC Purchases 76,961 Shares of Astria Therapeutics, Inc. $ATXS - MarketBeat
Bank Watch: Whats the MACD signal for Astria Therapeutics IncLong Setup & Fast Exit and Entry Strategy Plans - khodrobank.com
Aug PostEarnings: How cyclical is Astria Therapeutics Incs revenue streamJuly 2025 Chart Watch & Long Hold Capital Preservation Tips - خودرو بانک
Sentiment Review: Can Astria Therapeutics Inc. expand into new marketsQuarterly Performance Summary & Fast Gaining Stock Reports - khodrobank.com
Aug Action: Is Astria Therapeutics Inc trading at a discount2025 Historical Comparison & Verified High Yield Trade Plans - khodrobank.com
Real time pattern detection on Astria Therapeutics Inc. stockJuly 2025 Setups & Accurate Trade Setup Notifications - newser.com
Day Trade: Can Astria Therapeutics Inc reach all time highs this yearSell Signal & Technical Confirmation Alerts - khodrobank.com
Insider Sell: Can Astria Therapeutics Inc stock outperform in a bear marketGlobal Markets & Precise Buy Zone Identification - khodrobank.com
Returns Recap: Does Astria Therapeutics Inc have pricing powerMarket Trend Summary & AI Enhanced Execution Alerts - خودرو بانک
Earnings visualization tools for Astria Therapeutics Inc.Weekly Trade Report & Low Risk Investment Opportunities - newser.com
Building trade automation scripts for Astria Therapeutics Inc.2025 Trade Ideas & Weekly Momentum Picks - newser.com
Developing predictive dashboards with Astria Therapeutics Inc. dataWeekly Stock Summary & Safe Swing Trade Setup Alerts - newser.com
Backtesting results for Astria Therapeutics Inc. trading strategiesTreasury Yields & Community Consensus Trade Signals - newser.com
Astria Therapeutics Inc (ATXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.43%
0.09%
자본화:
|
볼륨(24시간):